As the first VEGF-targeted agent approved by FDA, bevacizumab, is used since February 2004, for the treatment of patients suffering from metastatic (m) CRC in combination with the standard chemotherapy treatment (as first-line treatment) [51]. The gene discussed is VEGFA; the disease is colorectal carcinoma.